Dermatology Products · LP-094
Nystatin Cream
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-094Dermatology Products
- Generic identity
- NystatinCream
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-094
- Generic identity
- Nystatin
- Presentation
- Cream
- Catalogue strength
- 100,000 IU/g
- Catalogue pack
- Tube 15 g / 30 g
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: nystatin.
- Dosage form: cream.
- Catalogue concentration: 100,000 IU/g.
- Catalogue tube options: 15 g and 30 g.
Layer 02 · Unresolved product-specific fields
- Exact potency/unit basis and whether “IU/g” is the controlled expression for the intended product.
- Cream base/excipients, preservative system and container-closure specification.
- Approved topical indication/site-of-use, age eligibility and application instructions.
- Tube-specific SKU status, storage, shelf life, registration and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 100,000 IU/g | Cream | — | Tube 15 g | Formula, potency-unit basis and controlled SKU evidence are not supplied. |
| B | 100,000 IU/g | Cream | — | Tube 30 g | Formula, potency-unit basis and controlled SKU evidence are not supplied. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Nystatin is an antifungal ingredient used in medicines for susceptible yeast infections. Topical formulations act at the skin surface and are distinct from oral preparations. For a cream presentation, the relevant educational context is cutaneous candidiasis and the assessment of a local fungal infection. A skin rash alone does not establish that Candida is the cause, and the ingredient name does not establish suitability for a particular patient.
Clinical context and therapeutic role
Clinical assessment considers the location and appearance of the lesion, duration, recurrence, and factors such as diabetes or immune suppression. A topical antifungal is not a treatment for every itchy rash, bacterial skin infection or systemic fungal illness. Persistent or worsening symptoms merit reassessment of the diagnosis and treatment. References below discuss nystatin generally; they do not confirm an authorized indication, age range or treatment schedule for a Luang Pharma product.
Selected safety context
Local burning, irritation and sensitivity can occur. New hives, facial swelling, difficulty breathing or a rapidly worsening rash require urgent medical assessment. Skin preparations should not be swallowed or applied to eyes. Use on infants, large damaged areas, or during pregnancy should be checked against the specific label and professional advice. Possible allergy to the active ingredient or cream excipients must be considered; the excipient composition is not established here.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a skin cream. Its unit strength and tube sizes are commercial presentation details, not directions for application. The cream base, preservative system, permitted application sites and patient age limits must be established from the approved dossier and leaflet.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
Review the diagnosis, treatment site, patient age, allergy history and need for reassessment. Product-level decisions require the current local label and verified supply documentation.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification/formula with potency-unit basis.
Approved topical label/leaflet.
Tube/container-closure specification and pack/SKU matrix.
Registration/market-status evidence for each exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: Nystatin topicalArchived source classification: US National Library of Medicine medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-094.
Professional enquiries
Request product-specific evidence for LP-094.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.